This Week in Psychiatry — Jun 30, 2026

Welcome to This Week in Psychiatry. This week we are covering four notable papers spanning the neurobiological pathways of substance use and reward, and clinical strategies to optimize and personalize our treatment regimens. Let's dive in.

We begin with a look at how neural circuits regulate reward-seeking behaviors, and how these pathways might explain clinical vulnerability in our patients. In a comprehensive review published in Biological Psychiatry, researchers explored the central glucagon-like peptide-one, or GLP-one, system, highlighting how its homeostatic and hedonic circuits influence both appetite and substance use [3]. The GLP-one system, which originates in the brainstem and projects to key metabolic and reward nuclei—including the hypothalamus, limbic system, and mesolimbic pathways—integrates motivated behavior with a person's physiological state. Activating these receptors essentially delivers a state-dependent behavior-ending signal that not only suppresses appetite and promotes satiety but also dampens the hedonic and motivational value of rewards. Critically, this dampening effect extends far beyond palatable foods. Because GLP-one receptor agonists can partially cross the blood-brain barrier, they engage these central networks to suppress drug-seeking behaviors. The clinical implication here is profound; while these agents are widely utilized for obesity and metabolic disorders, emerging evidence suggests they may have a highly valuable therapeutic application in treating substance use disorders characterized by reward-related maladaptive behaviors.

This intersection of substance use and altered brain chemistry is further illuminated by a study published in Molecular Psychiatry, which investigates how cannabis use interacts with brain glutamate levels across the psychosis spectrum [4]. Using ultra-high-field seven-Tesla proton magnetic resonance spectroscopy, researchers examined seventy-nine participants, including typically developing controls, individuals at clinical high risk for psychosis, and patients with established psychosis. They focused specifically on the anterior cingulate cortex, a region heavily implicated in cognitive control and emotional regulation. The investigators discovered that both lower anterior cingulate cortex glutamate levels and higher cannabis use were independently associated with more severe positive and negative psychotic symptoms. However, the most striking finding was an interaction effect: lower glutamate levels were significantly associated with higher positive symptoms specifically in cannabis users, but not in non-users. Furthermore, sensitivity analyses revealed that patients with psychosis who used cannabis had the lowest anterior cingulate cortex glutamate levels of all. This suggests that anterior cingulate cortex glutamatergic dysfunction may act as a transdiagnostic correlate of symptom burden, particularly in those with psychosis who use cannabis. For the practicing clinician, these findings reinforce the neurobiological risks of cannabis use in vulnerable populations and point toward glutamate-targeted interventions as a potential future therapeutic avenue for these patients.

Moving from neurobiological mechanisms to direct clinical management, our next theme focuses on how we can optimize and personalize existing and emerging psychiatric treatments. In a landmark study published in The Lancet Psychiatry, researchers in Germany addressed a long-standing debate in clinical practice: whether once-daily versus twice-daily lithium dosing regimens lead to different brain lithium profiles across the day [1]. While both dosing schedules are known to be clinically effective, they produce distinct serum lithium profiles, and it has remained unclear whether the brain experiences the same fluctuations. To investigate this, the authors conducted a repeated-measures, cross-sectional imaging study of forty-one euthymic individuals with bipolar disorder type one or two who were on stable lithium carbonate therapy. Using advanced lithium magnetic resonance imaging and matched serum sampling over a ten-hour period, they found that at twelve hours post-dose, both brain lithium signal intensity and serum lithium concentrations were equivalent across both dosing regimens. In the once-daily group, serum lithium steadily declined across the day, whereas in the twice-daily group, it rose after the morning dose before declining. Crucially, the brain lithium signal closely mirrored these serum profiles, showing more rapid equilibration in grey matter than in white matter or cerebrospinal fluid. For clinicians, the key takeaway is that brain lithium concentrations follow serum concentrations closely but align perfectly between regimens at the standard twelve-hour post-dose sampling mark. This directly validates our current therapeutic drug monitoring practices, confirming that a common reference range at twelve hours is highly applicable regardless of whether your patient takes their lithium once or twice a day, while also helping us tailor regimens to minimize side effects.

While optimizing traditional therapies like lithium is essential, the search for rapid-acting, personalized treatments for major depressive disorder and treatment-resistant depression remains a top priority. A review in Molecular Psychiatry outlines the rapid progress being made in this arena, from novel pharmacotherapies to advanced neuromodulation [2]. Over half of our patients with major depression experience an inadequate response to first-line serotonergic antidepressants, highlighting the urgent need for faster-acting alternatives. The authors highlight the transition of psilocybin and other neuroplastogens into late-stage clinical trials, alongside the clinical translation of repetitive transcranial magnetic stimulation. Notably, the Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT protocol, has demonstrated rapid-acting antidepressant effects and is now cleared by the Food and Drug Administration for treatment-resistant depression, representing a major step forward in personalized neuromodulation. Additionally, the review points to ongoing trials like ALTO-three hundred, which is evaluating an adjunctive treatment using electroencephalogram biomarkers, and other studies showing outcomes that vary based on specific genotype sequences. Despite these promising developments, the authors caution that real-world implementation still faces hurdles, including the challenge of maintaining blinding in psychedelic trials, the scalability of intensive neuromodulation protocols, and the ongoing need to validate these biomarkers. For clinicians, this review serves as a roadmap for the near future of depression care, suggesting we must prepare for a shift toward biomarker-guided and highly accelerated treatment protocols.

If you only have time for one paper this week, make it the German study on brain lithium kinetics published in The Lancet Psychiatry [1]. This study provides elegant, direct visual evidence that brain lithium levels closely mirror serum fluctuations throughout the day but align perfectly at the twelve-hour mark regardless of dosing frequency. This provides robust neuroimaging validation for our standard twelve-hour therapeutic drug monitoring window, giving clinicians the confidence to adjust dosing schedules to improve adherence or reduce side effects without worrying about destabilizing brain-level therapeutic concentrations.

Here are the key takeaways from this week in Psychiatry. First, when managing patients on lithium, you can confidently utilize the standard twelve-hour post-dose serum level to guide dosing for both once-daily and twice-daily regimens, as brain concentrations align at this timepoint despite different daily fluctuation profiles. Second, be highly vigilant about cannabis use in patients across the psychosis spectrum; cannabis use interacts with lower anterior cingulate cortex glutamate levels to significantly compound the severity of positive psychotic symptoms, highlighting a clear neurobiological vulnerability. Third, keep an eye on the central GLP-one system as a therapeutic target; its ability to dampen the hedonic and motivational value of rewards suggests that GLP-one receptor agonists may soon play a role in treating substance use disorders. Finally, prepare your practice for a paradigm shift in depression treatment, as rapid-acting options like the SAINT neuromodulation protocol and biomarker-guided therapies move closer to widespread clinical translation, though scalability and biomarker validation remain key challenges.

That's your roundup for This Week in Psychiatry. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week. One more note before you go: only 4 new papers of note met the bar since the last update — a quieter stretch for new literature. Still worth revisiting from recent updates: Targeting cortico-striatal-amygdalar networks via theta-band frontoparietal synchronization in opioid use disorder: a randomized tACS-fMRI Trial, in Molecular Psychiatry; and Acceptability and accuracy of point-of-care monitoring of lithium levels, in The British Journal of Psychiatry.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.